Showing results (1091-1100 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|October 19, 2010
Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cellsRaffaella Bosco, Marco Rabusin, Rebecca Voltan, et al.
Investigational New Drugs|September 17, 2009
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of responseBrigette B Y Ma, Vivian W Y Lui, Fan Fong Poon, et al.
Investigational New Drugs|September 17, 2009
DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signalingMoyan Liu, Lili Fu, Chunyan Liu, et al.
Investigational New Drugs|October 12, 2010
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium studyRobert J Morgan, Lucille Leong, Warren Chow, et al.
Investigational New Drugs|October 7, 2010
Antiangiogenic properties of an unusual benzo[k,l]xanthene lignan derived from CAPE (caffeic acid phenethyl ester)Giuseppina Basini, Laura Baioni, Simona Bussolati, et al.
Investigational New Drugs|December 4, 2010
Histone deacetylase inhibitors in Hodgkin lymphomaDaniela Buglio, Anas Younes
Investigational New Drugs|December 25, 2010
Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agentsRajeev Kumar, Vikas Verma, Amit Sarswat, et al.
Investigational New Drugs|March 9, 2011
DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057John A Hartley, Anzu Hamaguchi, Marie Suggitt, et al.
Investigational New Drugs|June 23, 2010
Cytotoxicity in human cancer cells and mitochondrial dysfunction induced by a series of new copper(I) complexes containing tris(2-cyanoethyl)phosphinesAlessandro Zanella, Valentina Gandin, Marina Porchia, et al.
Investigational New Drugs|June 10, 2010
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cellsWei-Gang Tong, Zeev Estrov, Yongtao Wang, et al.
Pageof 372